Kornimate/medical-research-clean huggingface dataset:
does anesthetic technique affect pneumatic tourniquet pressures in upper limb fracture surgery?

Conditions: Initial Systolic Blood Pressure (mmHg); Arterial Occlusion Pressure (mmHg); Tourniquet Time (Minutes); Quality of Bloodless Surgical Field (4 Point Scale); Initial Tourniquet Pressure (mmHg); Maximal Systolic Blood Pressure (mmHg); Maximal Tourniquet Pressure (mmHg)

Summary: in pneumatic tourniquet applications, the use of an individualized, lowest-effective tourniquet pressure (tp) has been recommended, in order to avoid pressure related complications. the aim of this study is to compare the effects of general anesthesia and axillary block on arterial occlusion pressure (aop) estimation based tp settings in upper limb fracture surgery. after, ethical committee approval 80 adult patients undergoing upper limb fracture surgery who gave their signed informed consent will be included. the age below 18 and above 85 years, american society of anesthesiology (asa) physical status \>2, any contraindication to axillary block or ga, adverse reaction history to anesthetic drugs, severe anemia, and refusal to give informed consent will be the exclusion criteria. the patients will be randomized to one of two study groups using a computer-generated randomization list to receive ga (group 1) and axillary block (group 2). main endpoints are initial and maximal blood pressures, aop, initial and maximal tps, and tourniquet time. additionally, the surgeon will evaluate the quality of bloodless surgical area with respect to the amount of blood using a 4-point scale (1: excellent= no blood in the surgical field, 2: good= some blood in the surgical field but no interference with surgery, 3: fair= blood in the surgical field but no significant interference with surgery, 4: poor= blood in the surgical field obscures the view) at the beginning, in the middle, and at the end of the surgical procedure. the patients will be observed for signs of tourniquet related complications by a blind investigator. spss 20.0 for windows is used for data analysis. the t test and the χ2 test will be used for continuous and categorical data respectively. a p value below 0.05 will be considered as statistically significant.


Eligibility criteria:
inclusion criteria: * adult patients undergoing upper limb fracture surgery exclusion criteria: * the age below 18 and above 85 years, * american society of anesthesiology (asa) physical status \>2 * any contraindication to axillary block or general anesthesia * any contraindication to tourniquet use * adverse reaction history to anesthetic drugs * severe anemia * refusal to give informed consent

Keywords: pneumatic tourniquet pressure upper extremity general anesthesia axillary brachial plexus block.
safety and efficacy of oxcarbazepine monotherapy in adults with partial seizures

Conditions: Epilepsy, Partial Seizures

Summary: this study is aimed to evaluate the efficacy, safety and tolerability of oxcarbazepine monotherapy in adults with partial seizures.


Eligibility criteria:
inclusion criteria: * males and females, 18 - 70 years of age; * diagnosis of epilepsy, partial seizures; * ineffective or intolerable present therapy with 1 antiepileptic drug, or none of previous therapy with antiepileptic drugs exclusion criteria: * progressive lesion of brain revealed by ct/mri that performed no earlier than 2 years prior to screening; * non-epileptic seizures; * drug or alcohol dependence during a year prior to screening; other protocol-defined inclusion/exclusion criteria may apply.

Keywords: partial epilepsy, oxcarbazepine, adults
ct guided percutaneous vertebroplasty for vertebral non-union following posterior fixation

Conditions: Vertebral Fracture; Vertebral Trauma

Summary: traumatic thoracolumbar vertebral fractures are frequently treated with posterior fixation (pf) and vertebral augmentation, but sometimes vertebral augmentation is not performed, being judged too risky under fluoroscopic guidance alone. an adjuvant ct/fluoroscopy guided percutaneous vertebroplasty (pvp) could be an option. the aim was to evaluate feasibility, safety and effectiveness of pvp in patients with vertebral non-union (vnu) following pf performed without concomitant vertebral augmentation. all patients treated in our institution with pvp between july 2015-july 2020 were retrospectively reviewed. patients treated with ct/fluoroscopy guided pvp under local anesthesia for symptomatic vnu following pf were selected. three criteria were established to assess cement distribution, considering vertebral filling of: 1)fracture cleft, 2)anterior two-thirds of the vertebral body, 3)from superior to inferior endplates. numeric pain rating scale (nprs) assessing grade of discomfort (0=no pain; 10=worst pain) and complications were evaluated before and one month after pvp.


Eligibility criteria:
inclusion criteria: * pvp performed between july 2015-july 2020 under combined ct and fluoroscopy guidance; * previous pf for traumatic non-neurological thoracolumbar vertebral fracture; * imaging evidence of vertebral non-union; * pain and functional impairment persisting for more at least one month after pf; * informed patient consent for pvp procedure under ct and fluoroscopy guidance; * previous multidisciplinary case discussion between spine surgeons and interventional radiologists. exclusion criteria: * age inferior to 18 years old * absence of complications due to orthopaedic hardware;
coolsculpting the flanks

Conditions: Body Fat Disorder

Summary: evaluate the safety and efficacy of non-invasive subcutaneous fat layer reduction in the flanks.


Eligibility criteria:
inclusion criteria * male or female subjects \> 22 years of age and \< 65 years of age. * subject has clearly visible fat on the flanks, which in the investigator's opinion, may benefit from the treatment. * no weight change exceeding 5% of body weight in the preceding month. * subject with body mass index (bmi) up to 30. bmi is defined as weight in pounds multiplied by 703 divided by the square of the height in inches. * subject agrees to maintain his/her weight (i.e., within 5%) by not making any major changes in their diet or exercise routine during the course of the study. * subject has read and signed the study written informed consent form. exclusion criteria * subject has had a surgical procedure(s) in the area of intended treatment. * subject has had an invasive fat reduction procedure (e.g., liposuction, mesotherapy) in the area of intended treatment. * subject has had a non-invasive fat reduction and/or body contouring procedure in the area of intended treatment within the past 12 months. * subject needs to administer, or has a known history of subcutaneous injections into the area of intended treatment (e.g., heparin, insulin) within the past month. * subject has a known history of cryoglobulinemia, cold urticaria, or paroxysmal cold hemoglobinuria. * subject has a known history of raynaud's disease, or any known condition with a response to cold exposure that limits blood flow to the skin. * subject has a history of bleeding disorder or is taking any medication that in the investigator's opinion may increase the subject's risk of bruising. * subject is taking or has taken diet pills or supplements within the past month. * subject has any dermatological conditions, such as moderate to excessive skin laxity, or scars in the location of the treatment sites that may interfere with the treatment or evaluation (stretch marks is not an exclusion). * subject has an active implanted device such as a pacemaker, defibrillator, or drug delivery system * subject is pregnant or intending to become pregnant during the study period (in the next 8 months). * subject is lactating or has been lactating in the past 6 months. * subject has a history of hernia in the areas to be treated. * subject is unable or unwilling to comply with the study requirements. * subject is currently enrolled in a clinical study of any other unapproved investigational drug or device. * any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.
preoperative vestibular rehabilitation effectiveness after vestibular schwannoma surgery

Conditions: Vestibular Schwannoma

Summary: vestibular schwannoma (vs) is a benign tumour from schwann cells surrounding the vestibular nerve, which slowly grows within the internal auditory canal and then into the cerebellopontine angle, leading to a gradual vestibular dysfunction. the slowly progressive alteration of vestibular function allows the gradual implementation of central adaptive mechanisms called vestibular compensation. the total unilateral vestibular deafferentation induced by the surgical tumour removal suddenly leads to a decompensation of this previously compensated situation, which explains why most patients report severe vertigo immediately after surgery and which is responsible for perturbations of the postural control (parietti-winkler et al., 2006, 2008, 2010, 2011). recently, gauchard et al. (2013) suggested that preoperative and regular physical activity would limit the adverse effects of surgical removal on balance control. also, patients benefited faster and better from the postoperative vestibular rehabilitation. thus, preoperative vestibular rehabilitation, including physical and balance exercises, could help to limit postoperative balance disorders and promote postoperative balance compensation. this could lead to a decrease in the duration and cost of the postoperative management and faster improvement of quality of life.

to test this hypothesis, the measured and perceived balance control of the patient and the quality of life will be assessed into two groups: one of two groups will receive preoperative vestibular rehabilitation, carried out by a physiotherapist, and the other not. the assessments will be conducted 45 days and 3 days before surgery, and then 8 days, 30 days, 90 days and 365 days after surgery.

Eligibility criteria:
inclusion criteria: * patients with unilateral vestibular schwannoma (stage i to iv according to the koos classification) with an indication for surgery. * patients gave their written informed consent * patients are affiliated to the french social welfare exclusion criteria: * disorders from the motor and/or somesthetic systems (especially the lower limbs) * contraindications to the scheduled functional assessments: ear pathology different from vestibular schwannoma such as cholesteatoma of the middle ear, tympanic membrane perforation, etc. * refusal of the surgical procedure

Keywords: posture unilateral vestibular deafferentation medical management preoperative vestibular rehabilitation neural plasticity
effect of kinesio tape on neck pain in lactating women

Conditions: Neck Pain Musculoskeletal

Summary: this study will be conducted to investigate the effect of kinesio tape on neck pain in lactating women.

neck pain is widely prevalent and can be exacerbated by poor posture and prolonged or repetitive positions-both of which are common in lactating mothers. research shows that a significant percentage of breastfeeding women experience musculoskeletal pain, often linked to specific postures such as the cross-cradle hold. prolonged forward head posture (fhp) and muscle imbalances in the neck-shoulder region further contribute to mechanical neck pain by placing excessive strain on muscles, joints, and connective tissues. kinesio taping (kt) is a non-pharmacological technique aimed at alleviating pain and improving functional movement. by lifting the skin slightly, kt is proposed to enhance local blood and lymphatic flow, reduce nociceptive signals, and stimulate proprioceptive feedback. multiple studies suggest kt can help correct posture, relieve muscle fatigue, and improve range of motion, thus offering a promising intervention for mechanical neck pain. these benefits are potentially valuable for lactating mothers, who are especially prone to postural stresses and neck discomfort due to the physical demands of breastfeeding.

Eligibility criteria:
inclusion criteria: * all women are complaining from neck pain. * their ages will be ranged from 20 to 30 years old. * their body mass index will not exceed 30 kg/m². * they are medically stable and consented to participate in the study. exclusion criteria: * cervical spondylosis. * cervical disc prolapse. * history of fracture of cervical spine.
a study to assess the effects of a light breakfast on the safety, tolerability, and pharmacokinetics of odanacatib (mk0822)

Conditions: Osteoporosis

Summary: this study will assess the safety and tolerability of single doses of odanacatib (mk0822) when administered with a light breakfast.


Eligibility criteria:
inclusion criteria: * subject is male and between the ages of 18 and 45 * subject is within 25% of ideal body weight and weighs between 55 and 95 kg * subject is in generally good health * subject is a nonsmoker exclusion criteria: * subject has multiple or severe allergies to food or medications * subject has a history of metabolic bone disease, kidney/bladder stones, or treatment with bisphosphonates * subject has any infections, including hiv * subject has donated blood or taken another investigational drug in the last month * subject consumes excessive amounts of caffeine or alcohol * subject has a history of any illness that may confound the results of the study or pose additional risk in administering the study drug
an evaluation of the effect of the erchonia fx-405 laser as an adjunctive treatment of periodontitis

Conditions: Periodontal Diseases; Periodontitis; Gum Disease

Summary: the purpose of this clinical study is to determine the effectiveness of the erchonia® fx-405 (manufactured by erchonia corporation (the company) in providing a noninvasive adjunctive treatment in combination with periodontal scaling and root planing for improving the treatment of periodontal disease.

the purpose of this clinical study is to determine the effectiveness of the erchonia® fx-405 (manufactured by erchonia corporation (the company) in providing a noninvasive adjunctive treatment in combination with periodontal scaling and root planing for improving the treatment of periodontal disease. this clinical study is a double-blind design, such that neither the subject, nor the investigators - the investigator administering the treatment with the erchonia® fx-405™ device (administration investigator) or the investigator recording the outcome measures (assessment investigator) - will be aware of whether the subject has been assigned to the active treatment test group or to the sham treatment control group until after the study is complete. all study subjects, regardless of treatment group assignment will receive active scaling and root planing standard of care therapy in addition to the active or sham therapy with the erchonia® fx-405™ device.

Eligibility criteria:
inclusion criteria: * subject has voluntarily signed a written informed consent form. * male or female 22 to 75 years of age, inclusive. * subject has no evidence of localized aggressive periodontitis. * tooth loss due to periodontitis of ≤ 4 teeth. * two or more teeth with the following characteristics: non 3rd molar, periodontitis: stage iii (severity) according to the interdental cal (at site of greatest loss) and rbl, as classified by the american academy of periodontology (aap), no evidence of caries, no abscess infection, no previous periodontal surgery within the prior 12 months * subject agrees to adhere to study provided home care instructions to maintain adequate oral hygiene during the study duration. * subject agrees to refrain from the use of smokeless chewing tobacco for the study duration. * subject agrees to refrain from exceeding 40 milligrams per day of inhaled nicotine, encompassing cigarettes, electronic cigarettes, and cigars. * subject agrees to refrain from engaging in any other treatments for his or her periodontitis that is outside the scope of this study during his or her participation in this study exclusion criteria: * gingival recession which may be genetic, induced secondary to orthodontic treatment, induced secondary to frenulum attachments, or present as a result of dental malocclusion. * history of oral cancer or hiv in the last 6 months * pregnant or intending to become pregnant in the next 8 months. * sensitivity to, or contraindication for, light therapy. * currently enrolled in a clinical study of an investigational drug or device.
comparison the value of several biomarkers of sepsis

Conditions: Systemic Inflammatory Response Syndrome; Sepsis

Summary: the purpose of this study is to describe the value of serum strem (soluble triggering receptor expressed on myeloid cells)-1, scd163, procalcitonin (pct), c-reactive protein (crp) concentrations, white blood cell (wbc) count and sofa score during sepsis and their clinical informative value in predicting outcome.

the investigators enrolled 130 subjects admitted to an icu: 30 cases with systemic inflammatory response syndrome (sirs), 36 cases with sepsis, 35 cases with and 29 with septic shock. results for strem (soluble triggering receptor expressed on myeloid cells)-1, scd163, procalcitonin (pct), c-reactive protein (crp) concentrations, white blood cell (wbc) count and sofa score were recorded on days 1, 3, 5, 7, 10, and 14.

Eligibility criteria:
inclusion criteria: * male and female aged 18 years old and over; * clinically suspected infection; * fulfilled at least two criteria of systemic inflammatory response syndrome (a) core temperature higher than 38 °c or lower than 36 °c (b)respiratory rate above 20/min, or pco2 below 32 mmhg (c) pulse rate above 90/min, and (d) white blood cell count greater than 12,000/μl or lower than \< 4,000/μl or less than 10% of bands. exclusion criteria: * those who fulfilled one below: * neutropenia (≤ 500 neutrophils/mm3) * hiv infection, and * patients or their relatives refused

Keywords: strem-1 scd163 pct crp wbc count sofa score sirs sepsis severity prognosis
dexmedetomidine infusion effect on hemodynamic variables during craniotomy

Conditions: Hemodynamic Instability; Supratentorial Neoplasms

Summary: there is no clear consensus among neuroanesthesiologists regarding which anesthetic regimen is optimal for craniotomy. propofol and short-acting opioids (such as remifentanil, fentanyl, or sufentanil) are commonly used. however, use of opioids is associated with increased risk of respiratory depression and postoperative nausea and vomiting. dexmedetomidine is a highly selective α2-adrenoreceptor agonist that has been considered as a useful and safe adjunct to anesthesia for various surgical procedures

the investigators designed this randomized, double-blind study to evaluate the effectiveness of administration of dexmedetomidine infusion at a dose of 0.5 µg/kg/h without loading dose during elective supratentorial craniotomy under ga. the investigators will compare intraoperative hemodynamics in both groups, intraoperative analgesic consumption, intraoperative blood loss, postoperative sedation scores, intraoperative need for rescue hypotensive agents, and finally the satisfaction of surgeons. to our knowledge, the present study is the first to evaluate the effect of dexmedetomidine infusion without loading dose in elective supratentorial craniotomy

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists- physical status (asa-ps) i and ii patients, * aged 18 to 65 years * 70-80 kg * both sexes * undergoing elective supratentorial craniotomy for tumor resection exclusion criteria: * patients under 18 years of age * pregnancy, * emergency surgery * patients with a glasgow coma score (gcs) less than 15. * those who had respiratory or cardiac dysfunction, renal insufficiency, liver impairment, or bleeding disorders

Keywords: postoperative analgesia craniotomy dexmedetomidine
fluid status of outpatients with dyspnea

Conditions: Dyspnea,; Acute Heart Failure Syndrome; Pulmonary Congestion

Summary: the purpose of this study is to determine the distribution of lung fluid status as reported by the imed-4 system in patients presenting to the emergency department or urgent care facility with shortness of breath.


Eligibility criteria:
inclusion criteria * shortness of breath as the most prominent presenting symptom * age greater ≥ 45 * willingness, ability, and commitment to participate in the study exclusion criteria * patients with any active implantable medical device * patients who are pregnant or lactating * patients who have tattoos and or non-intact skin directly under the electrode position * patients who have had past allergic reactions to medical grade adhesives * patients that are dialysis dependent * patients who have had a lung lobectomy * patients in whom the shortness of breath presentation is due to obvious non hf cause such as acute chest trauma * patients who have received nitrates (sub-lingual, topical or iv), diuretics or vasopressors ≥ 1 hour prior to imed-4 recording * patients who decline to have their backs photographed with the imed-4 device in position * patients who are receiving invasive or non-invasive positive airway pressure (pap) ventilation prior to or following presentation to the ed (self presentation or admission via ems). * severe co-morbidity or poor general physical/mental health that, in the opinion of the investigator, will not allow the subject to be a good study candidate (i.e. other disease processes, mental capacity, substance abuse, incarceration, shortened life expectancy, etc.)